An injection pen for Eli Lilly and Company’s weight loss drug Zepbound is displayed in New York City on December 11, 2023.
Brendan McDermid | Reuters
all doses Eli Lilly and Company Popular weight loss injections Zepp Bond Diabetes drug Mounjaro now available in U.S. renew Friday’s U.S. Food and Drug Administration drug shortage database.
A previous update said some doses of the treatment were still in short supply. Shortages of some Mounjaro doses and Zepbound doses as early as 2022 Join FDA Shortage List Earlier this year, following its U.S. Approval November.
Demand for weight loss and diabetes drugs has outstripped supply for months, leaving Eli Lilly and its rivals in trouble Novo Nordisk Invest billions of dollars to expand manufacturing.
The FDA update comes one day after Eli Lilly CEO David Ricks tell bloomberg Mounjaro and Zepbound shortages will end “soon”.
“I think actually today or tomorrow we plan to exit the process,” he told the media in an interview.
A spokesman for Eli Lilly did not immediately respond to a request for comment on the FDA’s Friday update.
As of Friday, all doses of Novo Nordisk’s diabetes injection Ozempic were available in the United States, according to the FDA. database. Meanwhile, the FDA said some doses of Novo Nordisk’s weight loss drug Wegovy are in limited supply.
